The Basser Center for BRCA hosted a panel discussion of the latest breakthroughs and discoveries for BRCA-related cancers.
Pancreatic cancer patient advocates Steven Merlin and Davi D’Agostino have joined to pool expertise and information for other patients.
Because Helene Avraham-Katz has the BRCA2 mutation, certain chemotherapies work better and she is eligible for specific clinical trials.
Chris Treubert started with one type of chemotherapy but when the results of genetic testing showed a BRCA mutation he changed treatment.
A new clinical trial tests a PARP inhibitor as maintenance treatment for pancreatic cancer patients with BRCA1/2 or PALB2 mutations.
Harvey Parker had genetic testing as part of his initial pancreatic cancer treatment. The BRCA2 mutation led him to a PARP inhibitor clinical trial.